Literature DB >> 12806204

Effect of tetrahydrobiopterin on blood pressure in rats after subtotal nephrectomy.

Eduardo Podjarny1, Sidney Benchetrit, Mauro Rathaus, Avishalom Pomeranz, Gloria Rashid, Janice Shapira, Jacques Bernheim.   

Abstract

BACKGROUND: Previous studies have shown that endothelial dysfunction after 5/6 nephrectomy (5/6 Nx) in rats is associated with decreased nitric oxide (NO) bioavailability and increased vascular superoxide production. Blood pressure is significantly increased by day 10 after surgery. Tetrahydrobiopterin (BH4) is a key cofactor of NO synthase. Suboptimal levels of BH4 result in uncoupling of NO synthase, low NO synthesis and augmented production of superoxide anions. The aim of this study was to evaluate whether BH4 supplementation may improve NO production and prevent the increase of blood pressure after 5/6 Nx.
METHODS: Three groups were evaluated: 5/6 Nx (untreated rats), BH4 (5/6 Nx rats treated with BH4, 10 mg/day i.p. for 10 days) and L-ARG (5/6 Nx rats treated with L-arginine, 260 mg/kg BW, p.o for 10 days). Systolic blood pressure (SBP), urinary nitrate excretion (UNO(3)) and creatinine clearance (CCR) were measured before surgery and on days 3 and 10 after surgery. Endothelial NO synthase (eNOS) protein content of mesenteric resistance vessels was measured at the end of the study.
RESULTS: SBP increased from 107 +/- 2 to 127 +/- 4 mm Hg in untreated 5/6 Nx rats (p < 0.01). By contrast, rats treated with BH4 or L-ARG remained normotensive. Ten days after 5/6 Nx, creatinine clearance decreased similarly in all groups. Both BH4 and L-ARG supplementation markedly increased UNO(3) excretion. The mesenteric vascular expression of eNOs protein was significantly higher in BH4 but not in L-ARG, compared with Nx rats.
CONCLUSIONS: BH4 supplementation prevents the earlier increase in blood pressure observed in rats after 5/6 Nx, possibly by upregulating eNOS in resistance vessels. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12806204     DOI: 10.1159/000071069

Source DB:  PubMed          Journal:  Nephron Physiol        ISSN: 1660-2137


  7 in total

Review 1.  Nutraceuticals as a potential adjunct therapy toward improving vascular health in CKD.

Authors:  Nicholas T Kruse
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2019-10-02       Impact factor: 3.619

2.  Tetrahydrobiopterin restores diastolic function and attenuates superoxide production in ovariectomized mRen2.Lewis rats.

Authors:  Jewell A Jessup; Lili Zhang; Tennille D Presley; Daniel B Kim-Shapiro; Hao Wang; Alex F Chen; Leanne Groban
Journal:  Endocrinology       Date:  2011-03-22       Impact factor: 4.736

3.  Tetrahydrobiopterin ameliorates the exaggerated exercise pressor response in patients with chronic kidney disease: a randomized controlled trial.

Authors:  Ann M Lin; Peizhou Liao; Erin C Millson; Arshed A Quyyumi; Jeanie Park
Journal:  Am J Physiol Renal Physiol       Date:  2016-03-09

4.  Effect of tetrahydrobiopterin and exercise training on endothelium-dependent vasorelaxation in SHR.

Authors:  François Guerrero; Sanéo Thioub; Christelle Goanvec; Sigrid Theunissen; Annie Feray; Costantino Balestra; Jacques Mansourati
Journal:  J Physiol Biochem       Date:  2012-09-26       Impact factor: 4.158

5.  Tetrahydrobiopterin lowers muscle sympathetic nerve activity and improves augmentation index in patients with chronic kidney disease.

Authors:  Jeanie Park; Peizhou Liao; Salman Sher; Robert H Lyles; Don D Deveaux; Arshed A Quyyumi
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2014-12-04       Impact factor: 3.619

Review 6.  Reactive oxygen species in vascular biology: implications in hypertension.

Authors:  R M Touyz; E L Schiffrin
Journal:  Histochem Cell Biol       Date:  2004-08-26       Impact factor: 4.304

Review 7.  Placental Ischemia Says "NO" to Proper NOS-Mediated Control of Vascular Tone and Blood Pressure in Preeclampsia.

Authors:  Ana C Palei; Joey P Granger; Frank T Spradley
Journal:  Int J Mol Sci       Date:  2021-10-19       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.